Is TB-500 Legal in North Carolina?

HealthRX.com

TB-500 is not clearly authorized for compounding in North Carolina

Print or save as PDF

Key numbers

  • 3 mg/mLProposed injection concentration in the nomination FDA reviewed; the peptide has no approved doseSource: fda.gov, as cited Nov 7, 2026
  • 2 mg to 15 mgVial sizes in which the peptide is sold online as research-use powder, outside any compounding pathwaySource: fda.gov, as cited Nov 7, 2026
  • 889 g/molMolecular weight of the synthetic peptide fragment sold under this nameSource: fda.gov, as cited Nov 7, 2026

See the public record for TB-500

  • What it is / A synthetic, N-acetylated 7-amino-acid fragment of thymosin beta-4, about 889 g/mol [1]
  • FDA approval / None; FDA found no approved drug containing TB-500, no Japanese pharmacopeia listing, and no approved product in Canada, Australia, the UK or the listed European countries [1]
  • Federal compounding lists / Absent from FDA's list for state-licensed pharmacies and physicians and from the outsourcing-facility list [2][3][4]
  • FDA safety-risk page / Sits in the 'nominated but withdrawn' table, not the active safety-risk table [8]
  • July 2026 advisory vote / Pharmacy Compounding Advisory Committee voted in favor of listing it; advice only [9][5]
  • HHS draft policy / Draft October 2026 statement of no intended enforcement action for the acetate form by injection; not an approval [5][6]
  • North Carolina / Chapter 90 governs the practice of medicine, including prescribing drugs for another person [7]
  • Sport / Prohibited at all times by WADA under section S2.3 [10][11]

Where the legal answer comes from

Two questions decide access to a peptide. The first is federal: is it an approved drug, and may a licensed pharmacy lawfully obtain it and put it into a syringe? The second is whether the state adds a rule of its own. Federal approval and compounding status are separate from North Carolina's practice-of-medicine rules, so the federal information below does not by itself determine who may prescribe, compound or administer TB-500 in the state.

Is TB-500 an FDA-approved drug?

No. FDA's July 2026 review found no USP or National Formulary monograph for TB-500, no FDA-approved drug containing it, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1].

Can a pharmacy in North Carolina compound it?

To compound a drug for an individual patient, a state-licensed pharmacy or physician must use a bulk substance that either complies with a USP or National Formulary monograph, is a component of an FDA-approved drug product, or appears on FDA's list of bulk substances that can be used in compounding [4]. TB-500 satisfies none of the three routes: no monograph exists, no approved product contains it, and it is not on the list [1][4].

FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and its separate list for outsourcing facilities (updated March 21, 2025) place TB-500 in none of their categories [2][3][4]. The category 1 policy, under which FDA generally does not intend to act against a compounder that meets the policy's conditions, does not reach it [4]. FDA also found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].

Questions worth asking

Choose the questions you want to keep

What FDA did in 2026

FDA's Pharmacy Compounding Advisory Committee discussed TB-500 free base and TB-500 acetate on July 23, 2026, for the use FDA evaluated, wound healing [9], and voted in favor of adding it to the bulks list, against the staff recommendation [5]. That vote is advice only and not binding; adding a substance to the list takes formal rulemaking [5].

FDA staff had proposed that neither the free base nor the acetate be added. The July 2026 briefing document cited inconsistent naming and missing impurity, aggregate and endotoxin data, unclear historical use, no evidence of effectiveness for wound healing, no human data of any kind, immunogenicity risk from injection, and the existence of FDA-approved wound treatments [1].

Does the HHS draft policy change that?

On October 28, 2026, HHS filed a draft enforcement-discretion policy covering six peptides, TB-500 among them (Federal Register document 2026-22192, publication scheduled for October 30, 2026, comments due two weeks after publication) [5][6]. It covers TB-500 acetate given by subcutaneous or intramuscular injection, and says HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician that compounds with it if the conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and the label statement 'This is a compounded drug product. Not for resale.' [5][6]

It is a draft. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public,' and HHS may revisit it if a safety signal or product quality issue arises. It is not an approval and does not put TB-500 on any list [5]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [5].

Does North Carolina have its own TB-500 law?

North Carolina's medicine statute, Chapter 90 of the General Statutes, defines the practice of medicine to include 'offering or undertaking to prescribe, order, give, or administer any drug or medicine for the use of any other individual' [7]. That definition is general: it does not itself say whether TB-500 may be prescribed or administered. TB-500's federal approval and compounding status are separate questions [7][1][2][3].

Is TB-500 banned in sport?

WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in section S2.3, growth factors and growth factor modulators. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [10]. It is on the 2026 List, in force since January 1, 2026 [10], and stays on the 2027 List [11]. That applies to athletes in sports that adopt the code, whatever a state's own rules say.

What is in the vial, and what is actually known?

TB-500 is a synthetic 7-amino-acid fragment, residues 17 to 23 of the 43-amino-acid protein thymosin beta-4, N-acetylated, with a molecular weight of about 889 g/mol [1]. It is not full-length thymosin beta-4 and not thymosin alpha-1, and FDA found several salts and derivatives, including different active moieties, sold under the same name [1]. It appears to have been first synthesized in 2003, with a veterinary preparation marketed from 2011 to boost performance in horses and greyhounds; it is sold online as research-use injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157 [1].

The human evidence base is empty. FDA searched PubMed, Embase, ClinicalTrials.gov and other databases and found no article in which TB-500 was given to a human, and none of the three papers the nominator cited involved TB-500 in humans [1]. In an in-vitro scratch-wound test, TB-500 at 50 micrograms/mL did not induce wound closure in fibroblast cultures; a shorter metabolite, N-acetylated LKKTE, did show activity [1]. There is no approved dose and no human dosing study; the nomination FDA reviewed proposed a 3 mg/mL lyophilized powder for subcutaneous or intramuscular injection [1].

Studies of full-length thymosin beta-4 are a different molecule and do not establish anything about the fragment. A phase 1 study of recombinant human thymosin beta-4 in healthy volunteers (54 in the single-dose part, 30 in the multiple-dose part) [12], two small dry-eye trials of thymosin beta-4 eye drops [13][14] and a 96-patient trial after heart attack [15] all tested the full protein.

What safety information exists?

FDA found no human pharmacokinetic or pharmacodynamic data for TB-500 by any route, and no nonclinical toxicity studies [1]. Its adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and its food and supplement complaint system retrieved two cases involving a blended TB-500 and BPC-157 product between January 1, 2004 and March 10, 2025, with no safety assessment [1]. FDA found no published case reports [1].

The agency's stated concern for injectable TB-500 is immunogenicity, potentially amplified by peptide aggregation and impurities; no study of TB-500 immunogenicity or aggregation was found [1]. FDA's review of BPC-157 describes a 40-year-old woman who used a research-purpose BPC-157 plus TB-500 (5 mg/5 mg) injection product subcutaneously twice daily and developed widespread skin hyperpigmentation and gum darkening within a week, recurring when she tried the product again two weeks later; because the product held two peptides, FDA could not tell which caused it [16].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, how many of the three compounding routes does TB-500 satisfy?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is TB-500 legal in North Carolina?
It is not clearly authorized for compounding: it is not FDA-approved and it is not on either of FDA's bulk-substance lists for compounding [1][2][3][4]. An October 2026 HHS draft says it does not intend to take enforcement action against certain pharmacies and physicians compounding TB-500 acetate for injection, but that is not an approval or a binding rule [5][6]. North Carolina's Chapter 90 defines the practice of medicine in general terms and does not itself settle TB-500's status [7].
Can a North Carolina clinician prescribe TB-500?
Chapter 90 of the North Carolina General Statutes defines the practice of medicine to include offering to prescribe, order, give or administer any drug for another person, and that general definition does not itself say whether TB-500 may be prescribed or administered [7]. Federally, TB-500 is on neither bulks list, and FDA found no pharmacy marketing a compounded TB-500 product [4][1].
Did the FDA advisory committee vote to allow TB-500 compounding?
The Pharmacy Compounding Advisory Committee voted in favor of adding TB-500 to the bulks list on July 23, 2026, against FDA staff's recommendation [9][5]. The vote is advice only and not binding, TB-500 is not on the list, and adding it takes formal rulemaking [5].
Does the October 2026 HHS policy make TB-500 legal?
No. It is a draft enforcement-discretion policy saying HHS does not intend to take enforcement action against certain pharmacies and physicians that compound TB-500 acetate for injection if the conditions are met [5][6]. The notice states it does not establish any rights for any person, and it does not put TB-500 on any list [5].
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic, N-acetylated 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4 [1]. Human studies of full-length thymosin beta-4, including eye-drop and intravenous recombinant products, do not show that TB-500 works or is safe [1].
Is TB-500 banned in sport?
Yes. WADA names thymosin-beta4 and its derivatives, including TB-500, in section S2.3 of its Prohibited List, and it is prohibited at all times, in and out of competition [10]. It appears on both the 2026 and 2027 Lists [10][11].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Does TB500 help with inflammation?

Not established. No human study has been found in which TB-500 was given for any purpose. FDA's review of wound healing found no evidence of effectiveness, and in an in-vitro scratch-wound test TB-500 at 50 micrograms/mL did not induce wound closure in fibroblast cultures.

Is TB-500 safe to use?

Safety is not established. FDA found no human pharmacokinetic or pharmacodynamic data and no nonclinical toxicity studies for TB-500, and its adverse-event database search retrieved no TB-500 reports. FDA's stated concern for injectable TB-500 is immunogenicity, potentially amplified by peptide aggregation and impurities.

Show all 16 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
  5. Official web page.
  6. Official web page.
  7. Chapter 90.
  8. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  9. U.S. Food and Drug Administration.
  10. World Anti-Doping Agency.
  11. World Anti-Doping Agency.
  12. Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
  13. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84.
  14. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6.
  15. Zhang Y, Dong Q, Bian X, Qiao Z, Cui C, Yang N, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758.
  16. U.S. Food and Drug Administration.
Evidence overview for Is TB-500 Legal in North Carolina?